Cadrenal Therapeutics to Pursue Partnerships for Phase 3-Ready CAD-1005 at BIO Convention
CVKD is trading near its 52-week low of $4.145 (4.7% above the low) on elevated volume (2.9× avg).
Summary
Cadrenal Therapeutics announced its participation in the BIO International Convention 2026 to host partnering meetings for its lead drug candidate, CAD-1005, which is Phase 3-ready, and its novel 12-LOX platform. This follows the April 30th news that CAD-1005 would advance to a pivotal Phase 3 trial. For this micro-cap biotech, actively seeking development and commercialization partners is a critical step for funding and advancing its lead asset, especially given its reported financial losses. CAD-1005 targets Heparin-induced Thrombocytopenia (HIT) with a potential $2 billion peak annual revenue. The convention takes place June 22–25, 2026, and any partnership announcements following this event would be significant.
At the time of this announcement, CVKD was trading at $4.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $4.15 to $15.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.